Related Experiment Video
Updated: Aug 7, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors
Qing Ma1, Olanrewaju O Okusanya, Patrick F Smith
1University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA.
Expert Opinion on Drug Metabolism & Toxicology
|July 26, 2006
Summary
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) interact with other drugs through the cytochrome P450 system. Understanding these pharmacokinetic interactions is crucial for effective HIV treatment regimens.
Area of Science:
- Pharmacology
- Virology
- Drug Metabolism
Background:
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are key antiretroviral agents targeting HIV-1 reverse transcriptase.
- Approved NNRTIs like delavirdine, efavirenz, and nevirapine exhibit distinct structural and pharmacokinetic profiles.
- These NNRTIs are metabolized by the cytochrome P450 (CYP) enzyme system.
Purpose of the Study:
- To review and summarize pharmacokinetic interactions associated with NNRTIs.
- To highlight the clinical significance of drug-drug interactions involving NNRTIs.
Main Methods:
- Literature review of pharmacokinetic interactions with NNRTIs.
- Analysis of drug metabolism pathways involving CYP enzymes.
- Summary of interactions with other antiretrovirals and concurrent medications.
Main Results:
- NNRTIs are substrates of the CYP enzyme system, leading to potential drug interactions.
- Interactions can occur with other antiretrovirals, concurrent medications, and complementary/alternative medicines.
- NNRTIs can act as inducers or inhibitors of CYP enzymes, affecting drug metabolism.
Conclusions:
- Clinically significant drug interactions are common with NNRTIs.
- Consideration of pharmacokinetic interactions is essential for designing effective combination HIV therapy.
- Updated knowledge on NNRTI interactions aids in optimizing patient treatment and minimizing adverse events.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...